palivizumab

Known as: PALI, Palivizumab [Chemical/Ingredient], anti-RSV 
A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Palivizumab was licensed in June 1998 by the Food and Drug Administration for the reduction of serious lower respiratory tract… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The prefusion state of respiratory syncytial virus (RSV) fusion (F) glycoprotein is the target of most RSV-neutralizing activity… (More)
  • figure 4
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Respiratory syncytial virus (RSV) infection is associated with subsequent recurrent wheeze. Observational studies… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as… (More)
Is this relevant?
Review
2008
Review
2008
Antibodies mediate humoral immune responses and play key roles in the defense of viral infection by the recognition… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Respiratory syncytial virus (RSV) is the leading cause of viral bronchiolitis and pneumonia in infants and children. Currently… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE Children who experience respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) early in life have… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
This report updates, expands, and replaces the previously published CDC "Guideline for Prevention of Nosocomial Pneumonia". The… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
  • Pediatrics
  • 1998
Objective. To determine the safety and efficacy of prophylaxis with palivizumab in reducing the incidence of hospitalization… (More)
Is this relevant?